Coeptis Therapeutics, Inc. (COEP) is a Biotechnology company in the Healthcare sector, currently trading at $12.99. It has a SharesGrow Score of 55/100, indicating a above average investment profile with 3 out of 7 criteria passed.
Valuation: COEP trades at a trailing Price-to-Earnings (P/E) of -6.2 (S&P 500 average ~25).
Financials: revenue is $1M, +0%/yr average growth. Net income is $12M (loss), growing at +25.3%/yr. Net profit margin is -874.3% (negative). Gross margin is -207.8% (+0 pp trend).
Balance sheet: total debt is $268,875 against $17M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 4.16 (strong liquidity). Debt-to-assets is 1.4%. Total assets: $20M.
Analyst outlook: 1 / 1 analysts rate COEP as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 100/100 (Pass), Past 0/100 (Fail), Health 67/100 (Partial), Moat 11/100 (Fail), Future 100/100 (Pass), Income 10/100 (Fail).
